
1. bmc gastroenterol. 2017 mar 9;17(1):39. doi: 10.1186/s12876-017-0596-7.

comparison long-term efficacy entecavir tenofovir in
treatment- naïve chronic hepatitis b patients.

park jw(1)(2), kwak km(3)(4), kim se(1), jang mk(5), suk kt(6), kim dj(6), park
sh(7), lee ms(7), kim hs(8), park ck(1).

author information: 
(1)department internal medicine, hallym university sacred heart hospital of
hallym university medical center, 22, gwanpyeong-ro 170 beon-gil, dongan-gu,
anyang-si, gyeonggi-do, 14068, republic korea.
(2)department biomedical gerontology, graduate school hallym university, 1 
hallymdaehak-gil, chuncheon-si, gangwon-do, 24252, republic korea.
(3)department occupational environmental medicine, hallym university
sacred heart hospital hallym university medical center, 22, gwanpyeong-ro 170 
beon-gil, dongan-gu, anyang-si, gyeonggi-do, 14068, republic korea.
(4)department environmental health, seoul national university school public
health, 1, gwanak-ro, gwanak-gu, seoul, 08826, republic korea.
(5)department internal medicine, kangdong sacred heart hospital hallym
university medical center, 18, cheonho-daero 173-gil, gangdong-gu, seoul, 05355, 
republic korea.
(6)department internal medicine, chuncheon sacred heart hospital hallym
university medical center, 77, sakju-ro, chuncheon-si, gangwon-do, 24253,
republic korea.
(7)department internal medicine, kangnam sacred heart hospital hallym
university medical center, 1, singil-ro, yeongdeungpo-gu, seoul, 07441, republic 
of korea.
(8)department internal medicine, kangdong sacred heart hospital hallym
university medical center, 18, cheonho-daero 173-gil, gangdong-gu, seoul, 05355, 
republic korea. hskim@hallym.or.kr.

background: limited studies directly comparing long-term
efficacy entecavir (etv) tenofovir disoproxil fumarate (tdf). this
study aimed compare long-term efficacy treatment-naïve
chronic hepatitis b (chb).
methods: 345 chb patients received first line therapy etv
(n = 200) tdf (n = 145) cohort, 210 patients analyzed using
propensity score matching, ratio 1:1.
results: two groups showed difference baseline characteristics. 
follow-up 12 months, hbv dna levels similarly suppressed groups
(etv vs. tdf; -5.01 vs. -5.242 log10iu/ml, p = 0.559). month 12, groups
showed difference terms serologic, biochemical virologic (vr)
response. multivariate analysis, initial virologic response 3 months
(ivr-3) independent factor vr 1 year. long-term follow-up, 
hbv dna levels strongly suppressed tdf etv hepatitis b e
antigen (hbeag) positive patients (p = 0.035), especially high viral load
(p = 0.012), although significant difference overall vr between
two groups. type antivirals independent factor long-term
vr.
conclusions: although either etv tdf, overall, may show comparable long-term
antiviral efficacy treatment-naïve chb, tdf might better regimen etv
in subgroup hbeag-positive chb, especially higher hbv dna levels.

doi: 10.1186/s12876-017-0596-7 
pmcid: pmc5345200
pmid: 28279168  [indexed medline]

